Studies - Challenges Memorize

0.0(0)
Studied by 1 person
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/61

encourage image

There's no tags or description

Looks like no tags are added yet.

62 Terms

1
New cards

Merikangas et al., 2007

epidemiological study (large n)
(disadvantages): cross-sectional; recall bias; based on DSM criteria


Findings:
BD ~ 1.4%

BDI ~ 1.0%

BDII ~ 1.1%

Subthreshold ~ 2.4%

2
New cards

McIntyre, 2009

Narrative review (risk of selection bias)


Findings:

~ >40% of patients are dissatisfied with/ treatment

Primarily regarding: weight gain and relapse prevention

3
New cards

Goodwin et al., 2011

Reviews efficacy for pharmacological treatment of acute mania


Systematic review and meta-analysis

commissioned by BAP guidelines


Findings:

Top ranked: RIS, OLZ, QTP

emphasizes treatment variability (effect size and tolerability differ across patients)

4
New cards

ONS, 2014

Survey outcome


Higher prevalence in women

only 1/3 of individuals with a common mental health disorder receive treatment


(disadvantages) self-report; cross-sectional

5
New cards

Papakostas et al., 2016

findings:

Patient preferences affect treatment outcome

6
New cards

Cipriani et al., 2018

meta-analysis 21 ADM

Treatment for acute major depression

ADM outperform placebo - modest effect size


Disadvantages:

Side effects reduce acceptability

withdrawal inflates placebo

trials did not test blinding integrity

Run-in design

7
New cards

Moncrieff, 2001

Drug-centered model

Active placebo reduces ADM efficacy

8
New cards

Nanni et al., 2012

Meta-analysis

Trauma reduces treatment outcome

Increases relapse rate

associate w/ chronic and persistent sx

greater impairment Ne

9
New cards

Nemeroff et al., 2003

RCT;

CBT vs SSRI

Trauma as a moderator


Disadvantage: small n, 1 ADM and 1 psychotherapy tested.

10
New cards

McIntyre et al., 2023

Systematic review.


30-50% of pts have TRD

TRD: research concepto; failed response after two or more adequate trials in a curren episode. Associate with poorer outcome,s higher mortality rates and lower quality of life of life.

Difficult-to-treat depression: Reflects the complexity, chronicity and impact of this diagnosis. Emphasize sperosnalized treatment. Accordance to Rush et al., 2018 mode. )

11
New cards

Cleare et al., 2015 BAP guidelines

Strategies for no response:

  1. Dose increase

    • poor evidence for SSRIs

  2. Switching

    • Better evidence; especially early switching

  3. Combination (2 adm) or Augmentation (ADM + another)


Relapse and recurrence risks

Low risk

High risk

high recurrent risk


12
New cards


Low risk

risk‑stratification categories


  • Single episode

  • Continue treatment 6–9 months after remission


13
New cards

High risk

risk‑stratification categories


  • More than one episode

    • Continue treatment ≥1 year


14
New cards

High recurrent risk

Risk stratification categories

  • 5+ episodes, or 2 episodes in 2 years

  • Consider long‑term maintenance treatment


15
New cards

Rush et al., 2004

STAR-D Methods and Results


12-14 week large scale longitudinal study to evaluate real-world effectiveness of depression treatment.

the largest and most methodologically rigorous study of sequential treatment in MDD, demonstrated that remission rates declined markedly with each treatment step


Level 1: Citalopram ~ 33-37% remission

Level 2: switch or augment / CBT ~ 25-31%

Level 3: switch or augment ~ 14%

Level 4: switch or augment ~ 14%


Important highlights:

  • Remission decreases with each treatment steps

  • This suggests that pharmacological stepping alone is insufficient for a substantial proportion of patients, highlighting the need for alternative approaches."

  • early and aggressive intervention is essential


Disadvantages

  • no double-blinding (open label design)

    • open-label design and lack of placebo control limit the certainty of its conclusions, as expectancy effects and clinician bias cannot be ruled out

  • patient-prefrence

  • CBT in only lv 2

  • High dropout rates

  • no placebo

  • heterogeneous sample


16
New cards

Warden et al., 2007

Comprehensive review of finding from STAR-D

Unfavorable predictors:

  • med/psych comorbidities

  • chronic depression

  • poor functioning

  • long current episode


better remission:

  • white

  • fem

  • marreid

  • higher education level

  • higher incoe

  • employed

  • privat einsurance


findings:

  • CT was as effective as switching/augmentation

  • Relapse risk increases sharply w/ each step

  • early intervention matters (!!!)

  • individualized treatment (tolerability, patience preference, prior response, comobridties)

  • No major differences between primary and secondary care


TRD mechanism

  1. no response

  2. failure to sustain response


17
New cards

Unfavorable predictors according to Warden et al., 2007

  • med/psych comorbidities

  • chronic depression

  • poor functioning

  • long current episode


18
New cards

Sachs et al., 2003

STEP-BD

large-scale study to evaluate real-world effectiveness


Two pathways:

  1. Standard care pathway

    • Follow usual guidelines (adjust, switch, combine, discontinue)

    • (adjust, switch, combine, discontinue)

  2. Personalized care pathway

    • randomized into clinical pathways

    • protocol-driven


(disadvantages)

  • not randomized

  • medicines are heterogeneous

  • therapy trial - self selected

  • no control over treatment

  • weak causal interference


19
New cards

Bowden et al., 2011

Clinical implications

  • BD requires phase-specific interventions

  • ADM caution

    • specific risk - TAOI & MAO

    • ADM did not improve depression, did not speed recovery and did not increase switching

    • higher risk when not combined

  • psychotherapy improved recovery

  • patients receiving psychotherapy were 1.58 times more likely to recover.

  • Recurrence occurs in approximately 50% of patients


predictors:

  • rapid cycling

  • early onset

  • residual symptoms

  • symptom abuse

  • comorbid anxiety

  • BD1


sleep disturbance diminishes functioning


20
New cards

Predictors of relapse in BD (Bowden et al., 2011)

rapid cycling

early onset

residual symptoms

comorbid anxiety

BD1


sleep disturbance diminish functioning

21
New cards

Goodwin & Jamison et al., 2007

Phases of Treatment


Acute - 6-12 w - Until response or remission (ideally)

Continuation - 7- 13 months - on-going

maintenance - prevents futures episodes (maintenance - after remission; continue stability) (prophylaxis - prevent new ep)




22
New cards

Miura et al., 2013

Meta-analysis and Review

Li and QTP good evidence to prevent relapse

Li - non-enriched samples

QTP - enriched samples

(can combine if with fluoxetine)

Li loweres suicide risk

Li maintenacne 0.6-0.8 mmol/l

23
New cards

Li et al., 2015


Systematic Review and Meta-analysis

CBT is the most evidence-based form of treatment


disadvantages:

Doesn’t account for biological aspects

used for less severe cases

requieres motivation and cognitive capacity

may overlook trauma-based processes

24
New cards

Structure of CBT

This therapy is:

present focused

directive and structured

time limited

aim - build self-help skills


25
New cards

Cognitive mechanisms


automatic thoughts - spontaneous and accessible and believable

intermediate thoughts - rules of living, conditional (“if…then…”)

26
New cards

Cognitive maintenance of depression

Vulnerability - dysfunctional scheme

Trigger events activate this (turning it into a vicious cycle)

Leads to:

negative thoughts

cognitive distortions

behviaoural responses

consequences

27
New cards

Antidepressant caution (Bowden et al., 2011)

specific risk - Tricyclic antidepressants and MAOIs

did not improve bipolar depression

did not speed recovery

higher risk when not combined

Psychotherapy improved recovery (1.58 x more likely)ja

28
New cards

Jaeger et al., 2006

Cross-sectional neuropsychological evaluation of MDD

6 month follow-up


Depression patients exhibited cognitive impriment when compared to HC

core issues: working memory, processing speed, executive functioning


Issues persisted after mood improved (!!)

cognitive impairment predicted functional outcome better than symptom severity.


Disadvantages:

small n (hospitalized n)

cross-sectional

29
New cards

Martínez-Arán et al., 2007

Cross-sectional neuropsychological evaluation of BD.

Studies further demonstrate that individuals with bipolar I disorder underperform when compared to healthy controls (Burdick et al., 2011)


core issues: working memory, attention, executive functioning

30
New cards

Miskowiak et al., 2018

Bipolar cognitive assessment

2-3 months after an acute episode (may be assessed every 5 years if impairment is detected)


Initial evaluation: SCIP & COBRA (provide a quantification of verbal learning, working memory and processing speed while also recounting subjective experience of his cognitive difficulties, respectively)


Evaluate if it is illness-related

That is not: secondary to medication, comorbidity or unhealthy life-style, due to organic brain disorder or dementia.

Address secondary causes if so.


What to do: recommendations for patients and their relative, Encourage compensation strategies, support & adjustments of expectation


•Track cognition over time, ideally at least every 5 years or when there is a reason to anticipate an assessment

31
New cards

Legemaat et al., 2022

meta-analysis of RCTs for CRT in MDD


preliminary findings

small-to -moderate effects

no evidence of log-term benefit

Effects strongest for processing speed and verbal learning


disadvantages:

small numbers of high-quality RCTS

small samples

CRT protocols varied

underpowered trials

32
New cards

cognitive impairment

Impairment in mental processes involved in learning, retrieving info, understanding , planning, resolving and making decisions.


They are heterogeneous across patients and are hard to discern from illness or medication effects.

33
New cards

Samamé et al., 2023

Meta-analysis of CRT for Bipolar

small to moderate effects

improvements: attention, executive functioning memory

Minimal effects on mood symptoms

No examination of psychosocial functioning (major gap)

CRT is safe and well-tolerated


(disadvantages )

  • Very few RCTs

  • No functional outcomes (work, social functioning)

  • BD samples highly heterogeneous (I vs II, euthymic vs symptomatic)

    • CRT protocols inconsistenC


34
New cards

Cognitive Remediation Therapy

Cognitive impairment is an underrated persistent issue within affectivee disorders.

(Millet & Burdick et al., 2021)- resiliency course


This type of of therapy targets persistent cognitive deficiencies.

Findings are preliminary (we need larger (RCTs)

Promotes metacongition (knowledge and regulation) and emphasizes strategy use


there is promising evidence, yet no replication Ani

35
New cards

Animal models

Are used for exploratory and developmental reasons, because regulations demand them to fulfill requirements, to investigate underlying mechanisms and are demanded by the public.


Have a low-construct validity (extent to which a tolls measures a theoretical/abstract concept).


validity of a procedure depends on the objectives of the experiment.


Disadvantages:

  • Do not capture subjective epxiernces

  • Psychological disorders are language based

  • No biormarkers

    • Cross-sectional analysis


36
New cards

Treatment-Resistant Depression

Focuses on an acute biological

Research definition

Failure of two or more adequate trials in current episode

Approach is many biomedical with a categorical endpoint (remission or not)

37
New cards

Difficult-to-treat Depression

It is a collaborative concept, representing a chronic illness model

Approach: biopsychosocial, capability approach, recovery movement, optimizing symptom control, minimizing impact of symptoms.

Endpoint is dimensional

Uses a 3D assessment model (McAllister-Williams et al., 2020):

  • person factors (genetics, trauma, etc)

  • illness factors (early onset, chronicity, comorbidity)

    • treatment factors (previous response, number/type, etc.)


38
New cards

McCloud et al., 2015

Meta-analysis and systematic review.

RCT of single-dose IV trials in bipolar depression


  • Rapid, large antidepressant effect

  • Strongest evidence: 24 - 72 hours

  • effect persists but weakness over days

  • works in ppl who failed multiple ADM

  • consistent across trials


RElevance:

  • TRD is not biologically “fixed” - rapid effect

  • glutamate and synaptic plasticity matter, shifting research away from sertononi-only networks


Disadvantages

  • very small RCTs

  • short follow-up

  • heterogeneous TRD definition

  • restricted populations

    • publication bias

Disadvantages

  • effect is rapid and short-lived

  • conclusions are limited due to small amounts of usable data

    • small n - underpowered

    • no active placebo

    • heterogeneous deign

  • Evidence base is too small and too low-quality to draw reliable conclusions


39
New cards

Zarate et al., 2006


RCT of a single-IV ketamine dose TRD

Rapid antidepressant effect lasting up to 7 days


relevance:

  • rapid effect is clinically significant demonstrating TRD is modifiable

  • glutamatergic mechanisms can produce rapid mood improvement

  • Proof-of-concept


Disadvantages

  • effect is rapid and short-lived


meta-analysis (Krystal et al., 2020)

40
New cards

FDA, 2011


Systematic review & meta-analysis

Biological efficacy of ECT is superior than Sham (ECT placebo) and medication.
ECT is more effective than meds; especially in severe depression

Support ECT as most effective acute treatment

Disadvantages:

  • older trials included

  • variation in ECT techniques

    • short follow-ups


41
New cards

Nordenskjold et al., 2012

Large observational cohort study

Predictors of ECT response:

  • older adults

  • more severe depression

  • psychosis

  • personality disorders

  • inpatients respond better than outpatients


Disadvantages:

  • observational (confounding factors; cannot infer causality)

    • limited generalizability


42
New cards

Jelovac et al., 2013

Systematic review & meta-analysis


Relapse rates for ECT

~ 27% at 3 months

~ 51% at 12 months

~ 50% at 24 months


Highly effective acutley but relapse is a major issue.

43
New cards

Dowlati et al, 2010

systematic review and meta-analysis of observational cohort studies

MDD has been associated with higher levels of ls of IL-6b and TNF-alpha

Elevations are seen even outside depressive episodes, suggesting trait‑level inflammation.

It is stipulated that elevation precedes depression (Findings imply inflammation may precede or increase vulnerability to depression)

Relevance

  • may be biomarkers

  • provides rational for a biological mechanism

  • provides rationale for immune-modulating treatments

    (Disadvantages):

  • observational biomarker studies of serum-plasma- cannot infer causality

  • high heterogeneity

  • peripheral cytokines may not reflect central inflammation


44
New cards

Solmi et al., 2021

Systematic review and meta-analysis of observational case-control studies


IL-6 is elevated in BD across depression, mania and euthymia.
Immune abnormalities are present outside mood episodes


Relevance:

  • IL-6 is potentially a trait marker

  • differentiate between BD from MDD (Bd shows more persistent inflammation)

  • provides rationale for immune-modulating treatments


disadvantages:

  • observational biomarker studies - can not infer causality

  • high heterogeneity

  • peripheral markers may not reflect central inflammation


45
New cards

Reiger et al., 1990

US epidemiological study


Bipolar patients had approximately 6 times higher odds of any substance use disorder compared to the general population.

  • Elevated rates also seen in MDD, but much lower than bipolar.

  • Alcohol, drug, and polysubstance misuse all markedly over‑represented.


Relevance:

  • establishes how common SUDs are in MD

  • suggest comorbidity is not incidental - major clinical feature

  • Provides the epidemiological foundation for why treatment is more complex in bipolar disorder.


Disadvantages:

  • cross sectional - cannot infer causality

  • DSM 90s critera

  • does not capture longitudinal course

  • self-report


46
New cards

Merikangas et al., 2008

20‑year prospective cohort study


Manic symptoms predicted later:

  • a fourfold increase in the risk of alcohol dependenc

  • a fivefold increase in cannabis misuse

  • and an elevenfold increase in benzodiazepine abuse.


RElevance:

  • suggest that mood dysregulation increases vulnerability to addiction

  • Supports shared neurobiological mechanisms (

  • Helps explain why bipolar disorder has high relapse rates and treatment resistance when SUD is present.


Disadvantges:

  • Observational → cannot prove causality.

  • Swiss cohort → may limit generalisability.

  • Substance use was partly self‑reported.

  • Does not fully separate effects of early environment or genetics.


47
New cards

Dalton et al., 2003

Bipolar patients with comorbid drug use disorder had significantly higher rates of suicide attempts than those without drug use.


relevance:
Demonstrates that SUD is not just comorbidity — it worsens prognosis.

Supports the argument that comorbid SUD → higher risk, more instability, more severe episodes.


Disadvantages:

  • Cross‑sectional → cannot determine directionality.

  • self-reported - recall bias

  • Does not differentiate between types of substances.


48
New cards

self-medication hypothesis

According to this hypothesis, individuals with a mood disorder may employ substances as a coping mechanism to address their mood dysregulation or symptoms.


For instance:

alcohol → anxiety or agitation

cananbis → calm mood

sedatives → distress

stimulants → counter depression re


Challenge of hypothesis: Although SUD worsen long-term instability in BD, a study shows (Stakowski et al., 2000) that 75 % of people with bipolar disorder do not change their alcohol consumption during a manic episode.

49
New cards

Reward Pathway

Possible underlying mechanism of addiction and affective disorders


Addictive substances dysregulate reward-learning mechanisms by generating dopamine signals larger and faster than natural rewards.


50
New cards

Possible effects of comorbidity SUD in affective disorders

higher risk of suicide

poorer adherence to treatment

poorer outcomes

higher relapse rates

51
New cards

Judd et al., 2002, 2003

Depressive symptoms overwhelmingly dominated the symptomatic periods in both bipolar I and bipolar II disorder.

In bipolar I, 67% of symptomatic weeks were depressive

In bipolar II, depressive symptoms accounted for 94% of symptomatic weeks

52
New cards

Methodological challenges of psychotherapy

There are in asymmetry in reporting.

Greatest benefits seem to derive from the therapeutic alliance.

Therapy can not be blinded and there may always be an expectancy effect that a waitlist comparator can not account for.

While ADM have mandatory reports of harm, therapy doesn’t when it can lead to increased instability.

53
New cards

Colom et al., 2003, 2009

2 RCTs done by the same group using the Barcelona program (21 sessions) . Structured: illness awareness, prodrome detection and adherence to a long-term trajectory.

5 year follow up


Findings:

  • diminshed relapse (especially manic)

  • prevented manic episodes

  • diminished hjopsitalisations


Relevance

  • effects are durable - persisting up to 5 years

  • strong evidence for pyschoeducation



54
New cards

Reinares et al., 2013

Narrative review comparing psychosocial interventions for Bipolar.

  • Best - structured group psychoeducation

    • long-lasting effect ts

  • CBT - most effective to prevent depressive spidoses

  • IPSRT - useful in acutely ill patients

    • may increase time of remission

  • Functional remediation - improves social and cognitive functioning


Relevance

  • phase-specific interventions

  • mehcnaism-specific eiinterventions

  • highlight that psychosocial interventions target different pathway s


Disadvantages

NOT a meta-analysis - selection bias

effects depend on illness stage and polarity

heterogenous

small n

55
New cards

Goodwin et al., 2022

Double-blinded clinical trial

single psychedelic session (psilocybin)

Active placebo


Findings:

  • 25 mg psilocybin produced significantly greater reductions in MADRS at 3 weeks vs 1 mg.

  • 26% were in remission at 12 weeks

  • Effects were strongest in the first 3–6 weeks and attenuated over time.

  • Adverse events were mostly mild/moderate and transient (headache, nausea, transient anxiety).


(disadvantage)

  • blindings is questionable as 25 mg is probably recognizable (1 mg)

  • Psychological support was standardised but still a potential confound.

  • Industry‑sponsored (COMPASS Pathways).

  • Excluded people with significant comorbidities → limits generalisability.

    • highly selected sample


56
New cards

Carhart-Harris et al. 2017

Open-label trial with 6 month follow-up

Evaluated safety and efficacy of psilocybin with psychological support in 20 patients with treatment-resistant depression

Key Results

  • Safety & Tolerability: The treatment was well tolerated with no serious or unexpected adverse events. Transient anxiety during onset was common. [1, 2, 3]

  • Short-Term Efficacy: Marked reductions in depressive symptoms occurred rapidly and lasted through the first 5 weeks (effect size Cohen's d = 2.2 at week 1 and 2.3 at week 5, p < 0.001). [1, 2]

  • Response and Remission: At 5 weeks post-treatment, 9 out of 20 patients (45%) met criteria for a clinical response, and 4 (20%) achieved complete remission. [1, 2]

  • Long-Term Follow-Up: Sustained positive improvements and reduced symptom scores remained apparent at the 3-month and 6-month evaluation marks for a subset of responders. [1, 2]


Produced 33% of remission at 6 months follow-up

  • Some participants maintained substantial, sustained improvement.

  • Qualitative reports suggested increased emotional openness and psychological flexibility.


Limitations

  • open-label

  • no control group

  • highly selected motivated patients

  • Intensive psychological support → unclear contribution of therapy vs drug

these estimates are inflated by the absence of controls and high expectancy effects.”

El

57
New cards

Elawad et al., 2021

Observational cohort-study

Predictors of higher response rates of ECT


  • psychotic features

  • old-age (especially w/ psychotic features)

  • severe depression

  • TRD

  • suicidality


disadvantages:

  • observational - cannot infer causality

    • heterogeneous sample


58
New cards

Wang et al., 2023

large prospective cohort study


Childhood maltreatment (any type) is significantly associated with the risk of depression in late-life depression.

High quality population-based evidence

Supports trauma-informed models


Disadvantages:

  • self-report (recall bias)

  • cannot infer causality

  • UK - cannot generalize

    • confounders


59
New cards

Barnes et al., 2012

Retrospective cohort study


Depression ate any stage of life increases the risk of dementia - may be prodromal to dementia


Depression may be hard to diagnose - avoid polypharmacy (anticholinergic burden: cumulative negative effect of multiple medicines block ACTh - age related sensitivity)


Disadvantages:

  • depression measured symptom questionnaire

  • cannot separate cause from prodrome

  • confounding


60
New cards

Anticholinergic burden

Anticholinergic side effects overlap with depressive symptoms, making the clinical picture messy. In older adults, depression can be difficult to diagnose because anticholinergic burden from multiple medications can mimic or worsen depressive and cognitive symptoms. Age‑related cholinergic vulnerability means even moderate polypharmacy can produce clinically significant cognitive slowing, apathy, and confusion.

61
New cards

psychedelics mechanism

activate 5‑HT2A receptors on cortical pyramidal neurons, increasing their excitability and producing a glutamate surge in the prefrontal cortex. This stimulates AMPA receptors and triggers BDNF release and mTOR signalling, which together promote synaptic plasticity.


5HT2A receptors → cortical pyramidal nuerons → producing a glutamate surge → stimulates AMP receptors → trigger BDNF release → promote synaptic plasticity

62
New cards

ketamine mechanism

blocks NMDA receptors on GABA interneurons, reducing inhibition and causing a glutamate surge in the prefrontal cortex. This enhances AMPA receptor activity and initiates BDNF release and mTOR signalling, leading to rapid increases in synaptic plasticity.


blocks NMDA on GABA interneurons → reduce inhibition → producing a glutamate surge → stimulates/enhances AMP receptors → trigger BDNF release → promote synaptic plasticity